Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
92.07
-1.73 (-1.84%)
Jan 29, 2026, 2:06 PM EST - Market open
Boston Scientific Revenue
Boston Scientific had revenue of $5.07B in the quarter ending September 30, 2025, with 20.34% growth. This brings the company's revenue in the last twelve months to $19.35B, up 21.62% year-over-year. In the year 2024, Boston Scientific had annual revenue of $16.75B with 17.61% growth.
Revenue (ttm)
$19.35B
Revenue Growth
+21.62%
P/S Ratio
7.17
Revenue / Employee
$365,075
Employees
53,000
Market Cap
136.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
| Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
| Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
| Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
| Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
| Dec 31, 2019 | 10.74B | 912.00M | 9.28% |
| Dec 31, 2018 | 9.82B | 775.00M | 8.57% |
| Dec 31, 2017 | 9.05B | 662.00M | 7.89% |
| Dec 31, 2016 | 8.39B | 909.00M | 12.16% |
| Dec 31, 2015 | 7.48B | 97.00M | 1.31% |
| Dec 31, 2014 | 7.38B | 237.00M | 3.32% |
| Dec 31, 2013 | 7.14B | -106.00M | -1.46% |
| Dec 31, 2012 | 7.25B | -373.00M | -4.89% |
| Dec 31, 2011 | 7.62B | -184.00M | -2.36% |
| Dec 31, 2010 | 7.81B | -382.00M | -4.67% |
| Dec 31, 2009 | 8.19B | 138.00M | 1.71% |
| Dec 31, 2008 | 8.05B | -307.00M | -3.67% |
| Dec 31, 2007 | 8.36B | 536.00M | 6.85% |
| Dec 31, 2006 | 7.82B | 1.54B | 24.48% |
| Dec 31, 2005 | 6.28B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Abbott Laboratories | 44.33B |
| Medtronic | 34.76B |
| Stryker | 24.38B |
| Koninklijke Philips | 20.86B |
| GE HealthCare Technologies | 20.25B |
| Zimmer Biomet Holdings | 8.01B |
| Smith & Nephew | 5.94B |
| Edwards Lifesciences | 5.88B |
BSX News
- 4 hours ago - Artisan Global Opportunities Fund Q4 2025 Portfolio Update - Seeking Alpha
- 7 days ago - Polen Global Growth Portfolio Q4 2025 Performance, Attribution & Portfolio Activity - Seeking Alpha
- 8 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR) - GlobeNewsWire
- 13 days ago - How Low Can Boston Scientific Stock Go When Markets Turn Sour? - Forbes
- 14 days ago - Boston Scientific Corporation (BSX) M&A Call Transcript - Seeking Alpha
- 14 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), Clearwater Analytics Holdings, Inc. (NYSE - CWAN) - GlobeNewsWire
- 14 days ago - Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach - Invezz
- 14 days ago - Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. - Barrons